Enzo loses US probe patent case, seeks new hearing
This article was originally published in Clinica
Diagnostics and healthcare products manufacturer Enzo Biochem has lost its US patent case, in which is was claiming that San Diego-based Gen-Probe's Neisseria gonorrhoeae nucleic acid probe diagnostic infringed its patent. The case, launched by Enzo in 1999, was resolved last week when judges at the US Court of Appeal decided 2-to-1 that the Enzo patent was invalid for lack of written description of the claimed invention. The decision confirmed an earlier lower court ruling.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.